Pharmacist-Led Strategies for Early Tardive Dyskinesia Detection, Patient Support, and Collaborative Care

The panel emphasizes the importance of setting clear, realistic expectations from the beginning, noting that these medications improve tardive dyskinesia but are not curative. They explain that early counseling should prepare patients for gradual titration, the possibility of side effects, and the need for continued engagement even if improvements are not immediately noticeable. Psychiatrists often introduce treatment, but pharmacists play a key role in reinforcing instructions, reviewing dosing plans, assessing tolerability, and answering follow-up questions. The discussion highlights the value of open communication among all team members to ensure consistent messaging and support patient confidence throughout therapy. By maintaining awareness of patient concerns and providing accessible guidance, pharmacists help patients stay motivated, understand therapeutic goals, and navigate the early phases of VMAT2 inhibitor treatment effectively.